Maternal-Infant Haplotypes and Tissue Rejection Pathways in Placental Villitis Examination

Overview

About this study

The purpose of this study is to identify genetic and molecular signatures of Villitis of Unknown Etiology (VUE) related to disease severity and poor pregnancy/fetal outcomes. In our first aim, we will evaluate the associations between maternal-infant HLA alleles, eplets and VUE. In our second aim, we will determine whether activation and upregulation of organ rejection genes/pathways is altered in VUE with poor outcomes.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria - Mother:

≥ 18 years of age.
Delivered a liveborn infant before 2020.
Have a documented placental pathology report and FFPE tissue.
Data on pregnancy outcome available in the electronic medical record.

Inclusion Criteria - Infant:

≥ 3 years of age and ≤ 6 years of age.

Exclusion Criteria - Mother:

< 18 years of age.
Delivered a stillborn or very preterm infant (< 26 weeks gestational age).
Delivered after 2020.
Does not have a placental pathology report or pregnancy outcome data available in the electronic medical record.
Placental diagnosis of chronic histiocytic intervillous or massive perivillous fibrin deposition.
Surrogate pregnancies.

Exclusion Criteria - Infant:

< 3 or > 6 years of age.
Abnormal genotype.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 12/21/23. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status	Contact
Rochester, Minn. Mayo Clinic principal investigator Elizabeth Ann Enninga, Ph.D.	Open for enrollment	Contact information: Elizabeth Ann Enninga Ph.D. (507) 538-7615 Enninga.ElizabethAnn@mayo.edu

Mayo Clinic Location

Status

Contact

Rochester, Minn.

Mayo Clinic principal investigator

Elizabeth Ann Enninga, Ph.D.

Open for enrollment

Contact information:

Elizabeth Ann Enninga Ph.D.

(507) 538-7615

Enninga.ElizabethAnn@mayo.edu

More information

Publications

Publications are currently not available

Clinical Trials